MedTrace Logo

DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain

NCT02318706 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 854

Last updated 2020-11-02

Study results available
· View outcomes & findings →

Summary

Investigate the efficacy and safety of DS-5565 in subjects with Diabetic Peripheral Neuropathic Pain (DPNP) in comparison to placebo

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

DRUG

DS-5565

DRUG

placebo

Sponsors & Collaborators

  • CMIC Co, Ltd. Japan

    collaborator INDUSTRY

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Quintiles Malaysia Sdn Bhd

    collaborator INDUSTRY

  • Daiichi Sankyo Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-06-29
Completion
2017-06-29

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02318706 on ClinicalTrials.gov